Induction paclitaxel/carboplatin in early stage non-small cell lung cancer

K. M W Pisters, M. G. Kris, Jr Bunn P.A., D. H. Johnson, J. C. Ruckdeschel, J. J. Crowley, R. J. Ginsberg

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung cancer. Nineteen of a planned 80 patients have been enrolled. To assure that patients meet the study's criteria for inclusion, rigorous physical and laboratory investigations are performed before, during, and after the preoperative chemotherapy and again before the post-surgical chemotherapy. Treatment includes two cycles of preoperative chemotherapy, followed within 3 to 6 weeks with thoracotomy. Up to three cycles of postoperative chemotherapy are planned, commencing 3 to 8 weeks after surgery, as tolerated. To date, 14 patients have completed induction chemotherapy, nine of whom have undergone surgical resection. Three patients have completed postoperative chemotherapy. The study treatment has been well tolerated with no unexpected toxicities. Very preliminary results suggest that perioperative paclitaxel/carboplatin appears to be a feasible and tolerable regimen in patients with early stage non-small cell lung cancer and warrants further investigation. More mature results may provide the basis for an intergroup randomized trial comparing this regimen with surgery alone for patients with early stage disease.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number4 SUPPL.12
StatePublished - 1997

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
Induction Chemotherapy
Feasibility Studies
Thoracotomy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Pisters, K. M. W., Kris, M. G., Bunn P.A., J., Johnson, D. H., Ruckdeschel, J. C., Crowley, J. J., & Ginsberg, R. J. (1997). Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Seminars in Oncology, 24(4 SUPPL.12).

Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. / Pisters, K. M W; Kris, M. G.; Bunn P.A., Jr; Johnson, D. H.; Ruckdeschel, J. C.; Crowley, J. J.; Ginsberg, R. J.

In: Seminars in Oncology, Vol. 24, No. 4 SUPPL.12, 1997.

Research output: Contribution to journalArticle

Pisters, KMW, Kris, MG, Bunn P.A., J, Johnson, DH, Ruckdeschel, JC, Crowley, JJ & Ginsberg, RJ 1997, 'Induction paclitaxel/carboplatin in early stage non-small cell lung cancer', Seminars in Oncology, vol. 24, no. 4 SUPPL.12.
Pisters KMW, Kris MG, Bunn P.A. J, Johnson DH, Ruckdeschel JC, Crowley JJ et al. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Seminars in Oncology. 1997;24(4 SUPPL.12).
Pisters, K. M W ; Kris, M. G. ; Bunn P.A., Jr ; Johnson, D. H. ; Ruckdeschel, J. C. ; Crowley, J. J. ; Ginsberg, R. J. / Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. In: Seminars in Oncology. 1997 ; Vol. 24, No. 4 SUPPL.12.
@article{bde9e38fd80a457d9a5a0668c1dbd4d7,
title = "Induction paclitaxel/carboplatin in early stage non-small cell lung cancer",
abstract = "In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung cancer. Nineteen of a planned 80 patients have been enrolled. To assure that patients meet the study's criteria for inclusion, rigorous physical and laboratory investigations are performed before, during, and after the preoperative chemotherapy and again before the post-surgical chemotherapy. Treatment includes two cycles of preoperative chemotherapy, followed within 3 to 6 weeks with thoracotomy. Up to three cycles of postoperative chemotherapy are planned, commencing 3 to 8 weeks after surgery, as tolerated. To date, 14 patients have completed induction chemotherapy, nine of whom have undergone surgical resection. Three patients have completed postoperative chemotherapy. The study treatment has been well tolerated with no unexpected toxicities. Very preliminary results suggest that perioperative paclitaxel/carboplatin appears to be a feasible and tolerable regimen in patients with early stage non-small cell lung cancer and warrants further investigation. More mature results may provide the basis for an intergroup randomized trial comparing this regimen with surgery alone for patients with early stage disease.",
author = "Pisters, {K. M W} and Kris, {M. G.} and {Bunn P.A.}, Jr and Johnson, {D. H.} and Ruckdeschel, {J. C.} and Crowley, {J. J.} and Ginsberg, {R. J.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL.12",

}

TY - JOUR

T1 - Induction paclitaxel/carboplatin in early stage non-small cell lung cancer

AU - Pisters, K. M W

AU - Kris, M. G.

AU - Bunn P.A., Jr

AU - Johnson, D. H.

AU - Ruckdeschel, J. C.

AU - Crowley, J. J.

AU - Ginsberg, R. J.

PY - 1997

Y1 - 1997

N2 - In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung cancer. Nineteen of a planned 80 patients have been enrolled. To assure that patients meet the study's criteria for inclusion, rigorous physical and laboratory investigations are performed before, during, and after the preoperative chemotherapy and again before the post-surgical chemotherapy. Treatment includes two cycles of preoperative chemotherapy, followed within 3 to 6 weeks with thoracotomy. Up to three cycles of postoperative chemotherapy are planned, commencing 3 to 8 weeks after surgery, as tolerated. To date, 14 patients have completed induction chemotherapy, nine of whom have undergone surgical resection. Three patients have completed postoperative chemotherapy. The study treatment has been well tolerated with no unexpected toxicities. Very preliminary results suggest that perioperative paclitaxel/carboplatin appears to be a feasible and tolerable regimen in patients with early stage non-small cell lung cancer and warrants further investigation. More mature results may provide the basis for an intergroup randomized trial comparing this regimen with surgery alone for patients with early stage disease.

AB - In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung cancer. Nineteen of a planned 80 patients have been enrolled. To assure that patients meet the study's criteria for inclusion, rigorous physical and laboratory investigations are performed before, during, and after the preoperative chemotherapy and again before the post-surgical chemotherapy. Treatment includes two cycles of preoperative chemotherapy, followed within 3 to 6 weeks with thoracotomy. Up to three cycles of postoperative chemotherapy are planned, commencing 3 to 8 weeks after surgery, as tolerated. To date, 14 patients have completed induction chemotherapy, nine of whom have undergone surgical resection. Three patients have completed postoperative chemotherapy. The study treatment has been well tolerated with no unexpected toxicities. Very preliminary results suggest that perioperative paclitaxel/carboplatin appears to be a feasible and tolerable regimen in patients with early stage non-small cell lung cancer and warrants further investigation. More mature results may provide the basis for an intergroup randomized trial comparing this regimen with surgery alone for patients with early stage disease.

UR - http://www.scopus.com/inward/record.url?scp=0030874763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030874763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030874763

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL.12

ER -